26 research outputs found
Application of Healthcare 'Big Data' in CNS Drug Research: The Example of the Neurological and mental health Global Epidemiology Network (NeuroGEN)
Neurological and psychiatric (mental health) disorders have a large impact on health burden globally. Cognitive disorders (including dementia) and stroke are leading causes of disability. Mental health disorders, including depression, contribute up to one-third of total years lived with disability. The Neurological and mental health Global Epidemiology Network (NeuroGEN) is an international multi-database network that harnesses administrative and electronic medical records from Australia, Asia, Europe and North America. Using these databases NeuroGEN will investigate medication use and health outcomes in neurological and mental health disorders. A key objective of NeuroGEN is to facilitate high-quality observational studies to address evidence-practice gaps where randomized controlled trials do not provide sufficient information on medication benefits and risks that is specific to vulnerable population groups. International multi-database research facilitates comparisons across geographical areas and jurisdictions, increases statistical power to investigate small subpopulations or rare outcomes, permits early post-approval assessment of safety and effectiveness, and increases generalisability of results. Through bringing together international researchers in pharmacoepidemiology, NeuroGEN has the potential to be paradigm-changing for observational research to inform evidence-based prescribing. The first focus of NeuroGEN will be to address evidence-gaps in the treatment of chronic comorbidities in people with dementia
A computational approach to compare regression modelling strategies in prediction research
Erratum to: Methods for evaluating medical tests and biomarkers
[This corrects the article DOI: 10.1186/s41512-016-0001-y.]
Evidence synthesis to inform model-based cost-effectiveness evaluations of diagnostic tests: a methodological systematic review of health technology assessments
Background: Evaluations of diagnostic tests are challenging because of the indirect nature of their impact on patient outcomes. Model-based health economic evaluations of tests allow different types of evidence from various sources to be incorporated and enable cost-effectiveness estimates to be made beyond the duration of available study data. To parameterize a health-economic model fully, all the ways a test impacts on patient health must be quantified, including but not limited to diagnostic test accuracy. Methods: We assessed all UK NIHR HTA reports published May 2009-July 2015. Reports were included if they evaluated a diagnostic test, included a model-based health economic evaluation and included a systematic review and meta-analysis of test accuracy. From each eligible report we extracted information on the following topics: 1) what evidence aside from test accuracy was searched for and synthesised, 2) which methods were used to synthesise test accuracy evidence and how did the results inform the economic model, 3) how/whether threshold effects were explored, 4) how the potential dependency between multiple tests in a pathway was accounted for, and 5) for evaluations of tests targeted at the primary care setting, how evidence from differing healthcare settings was incorporated. Results: The bivariate or HSROC model was implemented in 20/22 reports that met all inclusion criteria. Test accuracy data for health economic modelling was obtained from meta-analyses completely in four reports, partially in fourteen reports and not at all in four reports. Only 2/7 reports that used a quantitative test gave clear threshold recommendations. All 22 reports explored the effect of uncertainty in accuracy parameters but most of those that used multiple tests did not allow for dependence between test results. 7/22 tests were potentially suitable for primary care but the majority found limited evidence on test accuracy in primary care settings. Conclusions: The uptake of appropriate meta-analysis methods for synthesising evidence on diagnostic test accuracy in UK NIHR HTAs has improved in recent years. Future research should focus on other evidence requirements for cost-effectiveness assessment, threshold effects for quantitative tests and the impact of multiple diagnostic tests
Erratum to: Methods for evaluating medical tests and biomarkers
[This corrects the article DOI: 10.1186/s41512-016-0001-y.]
A computational approach to compare regression modelling strategies in prediction research
BACKGROUND: It is often unclear which approach to fit, assess and adjust a model will yield the most accurate prediction model. We present an extension of an approach for comparing modelling strategies in linear regression to the setting of logistic regression and demonstrate its application in clinical prediction research. METHODS: A framework for comparing logistic regression modelling strategies by their likelihoods was formulated using a wrapper approach. Five different strategies for modelling, including simple shrinkage methods, were compared in four empirical data sets to illustrate the concept of a priori strategy comparison. Simulations were performed in both randomly generated data and empirical data to investigate the influence of data characteristics on strategy performance. We applied the comparison framework in a case study setting. Optimal strategies were selected based on the results of a priori comparisons in a clinical data set and the performance of models built according to each strategy was assessed using the Brier score and calibration plots. Results : The performance of modelling strategies was highly dependent on the characteristics of the development data in both linear and logistic regression settings. A priori comparisons in four empirical data sets found that no strategy consistently outperformed the others. The percentage of times that a model adjustment strategy outperformed a logistic model ranged from 3.9 to 94.9 %, depending on the strategy and data set. However, in our case study setting the a priori selection of optimal methods did not result in detectable improvement in model performance when assessed in an external data set. CONCLUSION: The performance of prediction modelling strategies is a data-dependent process and can be highly variable between data sets within the same clinical domain. A priori strategy comparison can be used to determine an optimal logistic regression modelling strategy for a given data set before selecting a final modelling approach
How variation in predictor measurement affects the discriminative ability and transportability of a prediction model
Background and Objective: Diagnostic and prognostic prediction models often perform poorly when externally validated. We investigate how differences in the measurement of predictors across settings affect the discriminative power and transportability of a prediction model. Methods: Differences in predictor measurement between data sets can be described formally using a measurement error taxonomy. Using this taxonomy, we derive an expression relating variation in the measurement of a continuous predictor to the area under the receiver operating characteristic curve (AUC) of a logistic regression prediction model. This expression is used to demonstrate how variation in measurements across settings affects the out-of-sample discriminative ability of a prediction model. We illustrate these findings with a diagnostic prediction model using example data of patients suspected of having deep venous thrombosis. Results: When a predictor, such as D-dimer, is measured with more noise in one setting compared to another, which we conceptualize as a difference in “classical” measurement error, the expected value of the AUC decreases. In contrast, constant, “structural” measurement error does not impact on the AUC of a logistic regression model, provided the magnitude of the error is the same among cases and noncases. As the differences in measurement methods between settings (and in turn differences in measurement error structures) become more complex, it becomes increasingly difficult to predict how the AUC will differ between settings. Conclusion: When a prediction model is applied to a different setting to the one in which it was developed, its discriminative ability can decrease or even increase if the magnitude or structure of the errors in predictor measurements differ between the two settings. This provides an important starting point for researchers to better understand how differences in measurement methods can affect the performance of a prediction model when externally validating or implementing it in practice
How variation in predictor measurement affects the discriminative ability and transportability of a prediction model
Clinical epidemiolog
Methods for Evaluating Medical Tests and Biomarkers
Background and objectives: Prognostic models are, among other things, used to provide risk predictions for individuals who are not receiving a certain treatment, in order to assess the natural course of a disease and in turn guide treatment decisions. As treatment availability and use changes over time, researchers may be faced with assessing the validity of existing models in partially treated populations, and may account for treatment use in different ways. We aimed to investigate how treatment use contributes to the poor performance commonly observed in external validation studies, and to explore methods to address the issue. Methods: The effect of treatment use on the observed performance of a model was evaluated analytically. Development data sets representing untreated individuals were simulated using a logistic model and “optimal” models were developed using those sets. Validation sets drawn from the same theoretical population were simulated to receive an effective (binary) treatment. The prevalence and effectiveness of treatment were varied, with and without being dependent on true risk. Model performance in the validation sets was expressed in terms of calibration slope, observed:expected ratio (O:E) and C statistic. We examined the results of i) ignoring treatment, ii) restricting validation to untreated patients, and iii) adjusting the observed event rates to account for treatment effects. This was expressed through the difference (Δ) between each performance measure after applying a method and the value observed in the untreated set. Results: Validation of a model derived in untreated individuals in a treated validation set resulted in poorer model performance than that observed in the same population, if left untreated. Treatment of 50% of patients with a highly effective treatment (higher risk patients had a higher probability of receiving treatment; treatment effect odds ratio: 0.5), resulted in a decrease in the O:E from 1.0 to 0.7, and a decrease in the C statistic from 0.67 to 0.62 when compared to the observed statistics in an untreated set. This trend was observed across settings with different mechanisms for treatment allocation and different population risk distributions. As treatment prevalence and effectiveness increased, the observed model performance almost invariably decreased. Restricting the validation to only untreated individuals resulted in performance measures closer to those observed in the full untreated validation set, at the cost of precision (Δ O:E = 0.0; C statistic = 0.03). When treatment allocation was completely based on risk (I.e. according to a risk threshold), the restriction approach was less effective (ΔO:E = 0.0; ΔC statistic = 0.07). Increasing the observed event rates to account for treatment effects improved the observed model calibration, but this was highly sensitive to incorrect assumptions about treatment use and effectiveness. Conclusions: Validating a model designed to make predictions of the “natural course” of an individual’s health in a validation data set containing treated individuals may result in an underestimation of the performance of the model in untreated individuals. Current methods are not sufficient to account for the effects of treatment, and findings from such studies should be interpreted with caution
Methods for Evaluating Medical Tests and Biomarkers
Background and objectives: Prognostic models are, among other things, used to provide risk predictions for individuals who are not receiving a certain treatment, in order to assess the natural course of a disease and in turn guide treatment decisions. As treatment availability and use changes over time, researchers may be faced with assessing the validity of existing models in partially treated populations, and may account for treatment use in different ways. We aimed to investigate how treatment use contributes to the poor performance commonly observed in external validation studies, and to explore methods to address the issue. Methods: The effect of treatment use on the observed performance of a model was evaluated analytically. Development data sets representing untreated individuals were simulated using a logistic model and “optimal” models were developed using those sets. Validation sets drawn from the same theoretical population were simulated to receive an effective (binary) treatment. The prevalence and effectiveness of treatment were varied, with and without being dependent on true risk. Model performance in the validation sets was expressed in terms of calibration slope, observed:expected ratio (O:E) and C statistic. We examined the results of i) ignoring treatment, ii) restricting validation to untreated patients, and iii) adjusting the observed event rates to account for treatment effects. This was expressed through the difference (Δ) between each performance measure after applying a method and the value observed in the untreated set. Results: Validation of a model derived in untreated individuals in a treated validation set resulted in poorer model performance than that observed in the same population, if left untreated. Treatment of 50% of patients with a highly effective treatment (higher risk patients had a higher probability of receiving treatment; treatment effect odds ratio: 0.5), resulted in a decrease in the O:E from 1.0 to 0.7, and a decrease in the C statistic from 0.67 to 0.62 when compared to the observed statistics in an untreated set. This trend was observed across settings with different mechanisms for treatment allocation and different population risk distributions. As treatment prevalence and effectiveness increased, the observed model performance almost invariably decreased. Restricting the validation to only untreated individuals resulted in performance measures closer to those observed in the full untreated validation set, at the cost of precision (Δ O:E = 0.0; C statistic = 0.03). When treatment allocation was completely based on risk (I.e. according to a risk threshold), the restriction approach was less effective (ΔO:E = 0.0; ΔC statistic = 0.07). Increasing the observed event rates to account for treatment effects improved the observed model calibration, but this was highly sensitive to incorrect assumptions about treatment use and effectiveness. Conclusions: Validating a model designed to make predictions of the “natural course” of an individual’s health in a validation data set containing treated individuals may result in an underestimation of the performance of the model in untreated individuals. Current methods are not sufficient to account for the effects of treatment, and findings from such studies should be interpreted with caution